Understanding how EBV affects lymphoma in patients with weakened immune systems
EBV-Positive Diffuse Large B-cell Lymphoma: Defining Biologic Determinants of Disease Pathogenesis in Immunodeficiency
This study is looking at how the Epstein-Barr virus affects a type of cancer called diffuse large B-cell lymphoma, especially in people with weakened immune systems, like those with HIV, to help find better ways to diagnose and treat this illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-11222775 on NIH RePORTER |
What this research studies
This research investigates the role of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL), particularly in patients with weakened immune systems due to conditions like HIV. The study aims to identify the biological characteristics of EBV(+) DLBCL and how these relate to patient outcomes in different regions, including sub-Saharan Africa and the United States. By analyzing genomic data and clinical variables, the researchers hope to improve diagnostic methods and uncover new treatment targets for this aggressive cancer. Patients may contribute to a global cohort that enhances our understanding of this disease.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with diffuse large B-cell lymphoma who are also immunocompromised, particularly those with HIV.
Not a fit: Patients with DLBCL who are not immunocompromised or do not have EBV involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted therapies for patients with EBV-positive DLBCL.
How similar studies have performed: Previous research has shown that understanding viral contributions to cancer can lead to significant advancements in treatment, suggesting potential success for this approach.
Where this research is happening
Burlington, United States
- University of Vermont & St Agric College — Burlington, United States (Active)
Researchers
- Principal investigator: Volaric, Ashley Keller — University of Vermont & St Agric College
- Study coordinator: Volaric, Ashley Keller
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.